A migration is judged on what you do not lose.
We handle pharmaceutical website migration off legacy platforms such as Adobe Experience Manager, Sitecore and Drupal, with path-preserving redirects, permission mapping and crawl verification, so a domain does not reset the search history it spent years building.
A pharma website migration is rarely a content export. The hard parts are the URLs that must survive, the documents whose permissions have to travel with them, and the market-specific product data that is usually inconsistent between language versions before anyone touches it.
A per-path redirect map, the migrated content with its access rules intact, Search Console change of address, crawl verification against the old inventory, and a 404 monitoring window after go-live.
We identify the regulated systems, such as safety databases or validated software, before the migration plan is drawn up, and move the web estate around them rather than putting them at risk.
The surface we have had to preserve in pharmaceutical website migrations: documents, articles and country variants.
A distributor loses catalogue URLs. A biotech loses the backlinks its papers earned. A group loses country targeting. Pharmaceutical website migration starts from which of those actually applies.
What companies ask before moving a regulated site.
Not if the redirect mapping is done properly. Most migration losses come from blanket redirects to the homepage, chains that Google gives up following, or a Search Console change of address that was never submitted. A short dip while Google reprocesses is normal; a permanent drop is a mapping failure, not an inevitability.
Yes. We migrate from any platform, working from the database export when there is one and through structured scraping when access is restricted, which in enterprise estates is common. What decides the approach is what the source system exposes, and that is the first thing we establish.
They move with their access rules mapped alongside their paths. We have migrated document libraries in the thousands with inherited permissions intact. Treating permissions as a separate later task is how restricted material ends up publicly reachable after a move.
Typically two to four months for a corporate estate, and the variable is rarely the technical work. It is how long the content inventory takes to reconcile internally, particularly product data that differs between markets and no one currently owns.
Migration usually arrives alongside a redesign, a replatform or an accessibility review. These are the services it most often sits with.
A platform change, a domain change after a rebrand, or a site that already lost its rankings in a previous move. Tell us the context and we will tell you how we would approach the pharmaceutical website migration.